Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Enovis Corporation

Canaccord Genuity analyst Caitlin Cronin reiterated a Buy rating on Enovis yesterday and set a price target of $45.00. The company’s shares closed ...

Canaccord Genuity Remains a Buy on Enovis (ENOV)

The latest update is out from Enovis ( ($ENOV) ). On August 31, 2026, Enovis entered into a binding offer to acquire French-based eCential Robotics...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENOV	$18.27	+0.16%	1.72M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENOV	$18.27	+0.2%	1.72M
3
4
5
6

ENOV

Get Enovis Corporation Data in Excel

Get Enovis Corporation Data in Excel